Addendum
Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94
Report documents
-
Addendum
Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94
Dossier assessment
Indication:
Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy
Result of dossier assessment:
Due to new information from the commenting procedure now hint of a non-quantifiable added benefit.
Additional information
Federal Joint Committee (G-BA)
2020-05-14 A G-BA decision was published.
Project details
- Project no.
- A20-33
- Commission
- Commission awarded on 24.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed